Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kymera Therapeutics (KYMR)
NASDAQ:KYMR
Holding KYMR?
Track your performance easily
Earnings Data
Report Date
Feb 20, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.77Last Year’s EPS
-$0.25Same Quarter Last Year
Strong Buy
Based on 17 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 31, 2024
|% Change Since: -14.71%
|Next Earnings Date:Feb 20, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant advancements in Kymera's immunology pipeline with the initiation of KT-621's Phase 1 study and the advancement of KT-474 to Phase 2b. Financially, the company is well-positioned with substantial cash reserves. However, strategic shifts in oncology programs and extended timelines for KT-474 Phase 2 trials were noted as challenges.Company Guidance
During the Kymera Therapeutics Q3 2024 earnings call, the company provided several key updates and guidance on its pipeline. Notably, Kymera announced the initiation of a Phase 1 study for KT-621, a first-in-class oral STAT6 degrader, with plans to report results in the first half of 2025. The company highlighted the potential of KT-621 to transform treatment paradigms for diseases like atopic dermatitis and asthma. Kymera also updated on KT-474, an IRAK4 degrader, where partner Sanofi is expanding Phase 2 studies to accelerate the path to Phase 3 trials. Additionally, Kymera advanced KT-295, a new TYK2 clinical candidate, maintaining its timeline for a Phase 1 trial start in the first half of 2025. Financially, the company ended the quarter with $911 million in cash, providing a runway into mid-2027, and emphasized its strategic focus on its immunology pipeline.Initiation of KT-621 Phase 1 Study
Kymera has started the Phase 1 study of KT-621, a first-in-class oral STAT6 degrader, which marks the first STAT6 medicine to enter clinical development.
Advancement of KT-474 to Phase 2b
Kymera's KT-474, an IRAK4 degrader, is transitioning to fully powered Phase 2b studies, allowing a faster path to registrational Phase 3 studies.
Development of New TYK2 Lead Compound
Kymera has decided to advance a new compound, KT-295, as their lead TYK2 candidate due to its greater in vivo activity, without impacting development timelines.
Strong Financial Position
Kymera raised approximately $600 million in 2024, ending the third quarter with $911 million in cash, providing runway into mid-2027.
---
KYMR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
KYMR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 31, 2024 | $47.67 | $46.17 | -3.15% |
| Aug 07, 2024 | $41.42 | $40.31 | -2.68% |
| May 02, 2024 | $36.24 | $36.30 | +0.17% |
| Feb 22, 2024 | $38.67 | $40.49 | +4.71% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Kymera Therapeutics (KYMR) report earnings?
Kymera Therapeutics (KYMR) is schdueled to report earning on Feb 20, 2025, TBA Not Confirmed.
What is Kymera Therapeutics (KYMR) earnings time?
Kymera Therapeutics (KYMR) earnings time is at Feb 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is KYMR EPS forecast?
KYMR EPS forecast for the fiscal quarter 2024 (Q4) is -$0.77.
---